Starpharma Holdings Ltd - Asset Resilience Ratio
Starpharma Holdings Ltd (SPL) has an Asset Resilience Ratio of 69.74% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Starpharma Holdings Ltd (SPL) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Starpharma Holdings Ltd's Asset Resilience Ratio has changed over time. See SPL equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Starpharma Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Starpharma Holdings Ltd (SPL) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$18.25 Million | 69.74% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$18.25 Million | 69.74% |
Asset Resilience Insights
- Very High Liquidity: Starpharma Holdings Ltd maintains exceptional liquid asset reserves at 69.74% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Starpharma Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Starpharma Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Starpharma Holdings Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Starpharma Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 59.40% | AU$15.10 Million ≈ $10.68 Million |
AU$25.42 Million ≈ $17.99 Million |
-2.61pp |
| 2024-06-30 | 62.01% | AU$22.83 Million ≈ $16.15 Million |
AU$36.81 Million ≈ $26.05 Million |
-2.34pp |
| 2023-06-30 | 64.35% | AU$33.52 Million ≈ $23.72 Million |
AU$52.09 Million ≈ $36.85 Million |
-4.85pp |
| 2022-06-30 | 69.20% | AU$45.79 Million ≈ $32.40 Million |
AU$66.17 Million ≈ $46.82 Million |
-9.04pp |
| 2021-06-30 | 78.24% | AU$57.30 Million ≈ $40.54 Million |
AU$73.24 Million ≈ $51.82 Million |
+11.74pp |
| 2020-06-30 | 66.49% | AU$25.98 Million ≈ $18.39 Million |
AU$39.08 Million ≈ $27.65 Million |
-11.91pp |
| 2019-06-30 | 78.40% | AU$38.31 Million ≈ $27.10 Million |
AU$48.86 Million ≈ $34.57 Million |
-3.58pp |
| 2018-06-30 | 81.98% | AU$47.97 Million ≈ $33.94 Million |
AU$58.51 Million ≈ $41.40 Million |
-4.88pp |
| 2017-06-30 | 86.85% | AU$57.84 Million ≈ $40.92 Million |
AU$66.59 Million ≈ $47.12 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$59.04 Million ≈ $41.77 Million |
-- |
About Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more